Cases & Deals

Baxter Ventures invests in Opsonix

Clients Baxter International Inc.

Jones Day represented Baxter Ventures in connection with its purchase of Series A Convertible Preferred Stock in a private placement by Opsonix, Inc., an immunotherapy company focused on developing and commercializing a pathogen-extracting therapy designed to remove infectious pathogens and toxins from circulating blood.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.